Preclinical comparison in AR4-2J tumor-bearing mice of four radiolabeled 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid-somatostatin analogs for tumor diagnosis and internal radiotherapy

Endocrinology

Volumn 141, Issue 9, 2000, Pages 3304-3312

  Froidevaux, Sylvie ^a,b   Heppeler, Axel ^a   Eberle, Alex N ^a   Meier, Anne Marie ^a   Häusler, Marianne ^a   Beglinger, Christoph ^a   Béhé, Martin ^a   Powell, Pia ^a   Mäcke, Helmut R ^a  

^a UNIVERSITY CHILDREN S HOSPITAL   (Switzerland)

^b UNIVERSITY HOSPITAL BASEL   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

1,4,7,10 TETRAAZACYCLODODECANE 1,4,7,10 TETRAACETIC ACID; ANGIOPEPTIN; INDIUM 111; OCTREOTIDE; OCTREOTIDE[3 TYROSINE]; PENTETIC ACID; PENTETREOTIDE; SOMATOSTATIN DERIVATIVE; VAPREOTIDE; YTTRIUM 90;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER DIAGNOSIS; CANCER RADIOTHERAPY; CONTROLLED STUDY; DRUG CLEARANCE; DRUG CONJUGATION; DRUG DISTRIBUTION; DRUG PENETRATION; DRUG STRUCTURE; DRUG UPTAKE; FEMALE; ISOTOPE LABELING; MALIGNANT NEOPLASTIC DISEASE; MOUSE; NONHUMAN; PRIORITY JOURNAL;

EID: 0034456389     PISSN: 00137227     EISSN: None     Source Type: Journal    
DOI: 10.1210/endo.141.9.7683     Document Type: Article

References (43)

1. Hypothalamic polypeptide that inhibits the secretion of immunoreactive pituitary growth hormone
2. Somatostatin
3. Somatostatin receptors in human endocrine tumors
4. Somatostatin receptor subtype expression in human tissues: A prediction for diagnosis and treatment of cancer
5. Octreotide
6. The role of somatostatin and its analogs in the diagnosis and treatment of tumors
7. Somatostatin receptor scintigraphy
8. Somatostatin receptor scintigraphy: Its sensitivity compared with that of other imaging methods in detecting primary and metastatic gastrinomas
9. Somatostatin receptor: Scintigraphy and radionuclide therapy
10. 3]-octreotide: The Rotterdam experience with more than 100 patients
11. Somatostatin analogues for somatostatin-receptor-mediated radiotherapy of cancer
12. 1]-Octreotide: A case history
13. DOTATOC: A powerful new tool for receptor-mediated radionuclide therapy
14. Yttrium-90-labelled somatostatin-analogue for cancer treatment
15. 90Y-labelled antibody administration
16. 90Y-labelled biotins using three-step tumour targeting
17. Evaluation of the serum stability and in vivo biodistribution of CHX-DTPA and other ligands for yttrium labeling of monoclonal antibodies
18. 90Y- labeled B72.3 immunoconjugate (GYC-DTPA) in beagle dogs
19. Yttrium-90-labeled antibody for therapy: Labeling by a new macrocyclic bifunctional chelating agent
20. Nature of the bifunctional chelating agent used for radioimmunotherapy with yttrium-90 monoclonal antibodies: Critical factors in determining in vivo survival and organ toxicity
21. Binding properties of somatostatin receptor subtypes
22. Detection of somatostatin receptor subtype 2 (SSTR2) in established tumors and tumor cell lines: Evidence for SSTR2 heterogeneity
23. Radiometal labelled macrocyclic chelator derivatised somatostatin analogue with superb turnout targeting properties and potential for receptor mediated internal radiotherapy
24. A microplate binding assay for the somatostatin type-2 receptor (SSTR2)
25. Affinity profiles for human somatostatin receptor SST1=SST5 of somatostatin radiotracers selected for scintigraphic and radiotherapeutic use
26. Differential regulation of somatostatin type 2 receptor (sst 2) expression in AR4-2J tumor cells implanted into mice during octreotide therapy
27. Expression and localization of somatostatin receptor SSTR1, SSTR2, and SSTR3 messenger RNAs using in situ hybridization
28. Characterization of somatostatin receptor subtypes
29. Mechanisms of heterogeneous distribution of monoclonal antibodies and other macromolecules in tumors: Significance of elevated interstitial pressure
30. Amino acid infusion blocks renal tubular uptake of an indium-labelled somatostatin analogue
31. Reduction of renal uptake of monoclonal antibody fragments by amino acid infusion
32. 111In-labeled somatostatin analogues for tumor scintigraphy and radionuclide therapy
33. Expression of MDR1 (multidrug resistance) gene and its protein in normal human kidney
34. P-glycoprotein functions and substrates: Possible roles of MDR1 gene in the kidney
35. Competition of hydrophobic peptides, cytotoxic drugs, and chemosensitizers on a common P-glycoprotein pharmacophore as revealed by its ATPase activity
36. Interaction of combinations of drugs, chemosensitizers, and peptides with the P-glycoprotein multidrug transporter
37. Molecular and pharmacological characterization of somatostatin receptor subtypes in adrenal, extraadrenal, and malignant pheochromocytomas
38. Identification of somatostatin receptor subtypes and an implication for the efficacy of somatostatin analogue SMS 201-995 in treatmeat of human endocrine tumors
39. Distribution of somatostatin receptor messenger RNAs in the rat gastrointestinal tract
40. T lymphocytes isolated from the hepatic granulomas of schistosome-infected mice express somatostatin receptor subtype II (SSTR2) messenger RNA
41. Expression of somatostatin receptor subtype 2 mRNA in human lymphoid cells
42. Activation of rat thymocytes selectively up-regulates the expression of somatostatin receptor subtype-1
43. Local up-regulation of neuropeptide receptors in host blood vessels around human colorectal cancers